Vacancy for a Physician (Research) in the Epidemiology Branch, NHLBI
The National Heart, Lung, and Blood Institute (NHLBI) – one of the largest institutes of the National Institutes of Health (NIH) – is seeking an exceptional and motivated physician scientist for the Epidemiology Branch, Division of Cardiovascular Sciences (DCVS). The Epidemiology Branch supports, designs, and conducts research and supports training in cardiovascular epidemiology, as well as provides population science expertise in other disease areas in NHLBI’s mission, including lung, blood, and sleep (LBS) disorders. Studies in heart, lung, blood, and sleep (HLBS) diseases are conducted to identify temporal trends and population distributions of disease and include single- and multi-center observational studies of the development, progression, and treatment of HLBS disorders. Studies identify environmental, social, lifestyle, physiological, and genetic risk factors for disease and risk factor development, including characterization of multi-omic signatures as well as gene/gene and gene/environment interactions.
The Epidemiology Branch provides leadership and oversight for several large longitudinal cohort studies including the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Coronary Artery Risk Development in Young Adults Study, the Framingham Heart Study, the Hispanic Community Health Study—Study of Latinos, the Jackson Heart Study, Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort Study, the Multi-Ethnic Study of Atherosclerosis, the Risk Underlying Rural Areas Longitudinal Study, the Strong Heart Study, and the Women’s Health Initiative. The Epidemiology Branch also shares leadership responsibility for several genomics programs and projects, including the Trans-Omics for Precision Medicine (TOPMed) program with over 155,000 whole genome sequences in diverse populations.
The successful candidates will be responsible for providing scientific and technical leadership and guidance related to the planning, development, and implementation of research in the areas of data science, precision medicine, clinical informatics, health disparities, social epidemiology, or women’s health related topics. The selected candidate for the position will be responsible for the overall programmatic direction of research in one or more of these areas in the Epidemiology Branch and leading and working with teams throughout DCVS/NHLBI. The ideal candidate will have an outstanding record of research accomplishments and experience with clinical- and/or population-based observational studies in chronic disease epidemiology with excellent interpersonal and communication skills and the ability to develop and oversee complex research programs.
Qualifications
Required
- U.S. citizen
- Doctor of Medicine, Doctor of Osteopathic Medicine or equivalent from a school in the United States or Canada. A Doctor of Medicine or equivalent degree from a foreign medical school must provide education and medical knowledge equivalent to accredited schools in the United States.
Strong candidates will possess the following qualifications
- Training and expertise in chronic disease epidemiology and in at least one of the following areas: molecular biology, genetics, multi-omics, and/or bioinformatics; clinical informatics and/or phenomics; health disparities and social determinants of health; and/or women’s health, ideally including maternal health
- Experience with clinical- and/or population-based observational studies in cardiovascular epidemiology
- Ability to synthesize research findings and develop a broad vision that will advance cardiovascular disease prevention and treatment
- Skill in communicating with scientists and with a sophisticated lay audience
To Apply
Visit https://www.nhlbi.nih.gov/about/working-at-nhlbi/job-opportunities to access the link to the NHLBI Physician job announcement (GS-13/14 or GP 14), which will open from November 2 to November 11, 2020.
For More Information
Contact Yuling Hong, MD, PhD at yuling.hong@nih.gov, Sean Coady, MS, MA at coadys@nhlbi.nih.gov, or Jared Reis, PhD at reisjp@nhlbi.nih.gov.
The U.S. Department of Health and Human Services (HHS), NIH, and NHLBI are equal opportunity employers committed to equity, diversity, and inclusion.
Vacancy for a Clinical Trials (Studies) Specialist in the Epidemiology Branch, NHLBI
The National Heart, Lung, and Blood Institute (NHLBI) – one of the largest institutes of the National Institutes of Health (NIH) – is seeking an exceptional and motivated candidate to serve as Clinical Trials (Studies) Specialist within the Epidemiology Branch, Division of Cardiovascular Sciences (DCVS). The Epidemiology Branch supports, designs, and conducts research and supports training in cardiovascular epidemiology, as well as provides population science expertise in other disease areas in NHLBI’s mission, including lung, blood, and sleep (LBS) disorders. Studies in heart, lung, blood, and sleep (HLBS) diseases are conducted to identify temporal trends and population distributions of disease and include single- and multi-center observational studies of the development, progression, and treatment of HLBS disorders. Studies identify environmental, social, lifestyle, physiological, and genetic risk factors for disease and risk factor development, including characterization of multi-omic signatures as well as gene/gene and gene/environment interactions.
The Epidemiology Branch provides leadership and oversight for several large longitudinal cohort studies including the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Coronary Artery Risk Development in Young Adults Study, the Framingham Heart Study, the Hispanic Community Health Study—Study of Latinos, the Jackson Heart Study, Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort Study, the Multi-Ethnic Study of Atherosclerosis, the Risk Underlying Rural Areas Longitudinal Study, the Strong Heart Study, and the Women’s Health Initiative. The Epidemiology Branch also shares leadership responsibility for several genomics programs and projects, including the Trans-Omics for Precision Medicine (TOPMed) program with over 155,000 whole genome sequences in diverse populations.
Successful Clinical Trials (Studies) Specialist candidates will be familiar with project management techniques and be responsible for managing and overseeing clinical, operational, and administrative activities for one or more of the above mentioned cohort studies; ensure compliance with ethical and regulatory aspects of clinical research; and promote the safety and well-being of participants. Candidates will be expected to establish overall priority for the oversight of clinical research activities; work well in and lead teams composed of other staff members; and have excellent written and oral communication skills. Experience managing and overseeing clinical and operational activities of a clinical research program is desirable.
Qualifications
Required
- U.S. citizen
- Bachelor’s degree with major academic study related to the medical field, health sciences, or allied sciences appropriate to the work of the position
Strong candidates will possess the following qualifications
- Graduate-level degree with major academic study related to the medical field, health sciences, or allied sciences appropriate to the work of the position
- Clinical research program management experience
- Excellent written and oral communication skills
- Ability to work well in a team environment
To Apply
Visit https://www.nhlbi.nih.gov/about/working-at-nhlbi/job-opportunities regularly to access the link to the NHLBI Clinical Trials (Studies) Specialist job announcement (GS-12/13), which will open mid-November 2020.
For More Information on the Position or the Specific Date of the Job Announcement in order to Apply
Contact Yuling Hong, MD, PhD at yuling.hong@nih.gov, Sean Coady, MS, MA at coadys@nhlbi.nih.gov, or Jared Reis, PhD at reisjp@nhlbi.nih.gov.
The U.S. Department of Health and Human Services (HHS), NIH, and NHLBI are equal opportunity employers committed to equity, diversity, and inclusion.
The National Heart, Lung, and Blood Institute (NHLBI) – one of the largest institutes of the National Institutes of Health (NIH) – is seeking exceptional and motivated candidates to serve as Health Scientist Administrators within the Epidemiology Branch, Division of Cardiovascular Sciences (DCVS). The Epidemiology Branch supports, designs, and conducts research and supports training in cardiovascular epidemiology, as well as provides population science expertise in other disease areas in NHLBI’s mission, including lung, blood, and sleep (LBS) disorders. Studies in heart, lung, blood, and sleep (HLBS) diseases are conducted to identify temporal trends and population distributions of disease and include single- and multi-center observational studies of the development, progression, and treatment of HLBS disorders. Studies identify environmental, social, lifestyle, physiological, and genetic risk factors for disease and risk factor development, including characterization of multi-omic signatures as well as gene/gene and gene/environment interactions.
The Epidemiology Branch provides leadership and oversight for several large longitudinal cohort studies including the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Coronary Artery Risk Development in Young Adults Study, the Framingham Heart Study, the Hispanic Community Health Study—Study of Latinos, the Jackson Heart Study, Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort Study, the Multi-Ethnic Study of Atherosclerosis, the Risk Underlying Rural Areas Longitudinal Study, the Strong Heart Study, and the Women’s Health Initiative. The Epidemiology Branch also shares leadership responsibility for several genomics programs and projects, including the Trans-Omics for Precision Medicine (TOPMed) program with over 155,000 whole genome sequences in diverse populations.
Successful Health Scientist Administrator candidates will be responsible for providing scientific and technical leadership and guidance related to the planning, development, and implementation of research in the areas of data science, precision medicine, clinical informatics, health disparities, social epidemiology, or women’s health related topics. The selected candidates for these positions will be responsible for the overall programmatic direction of research in one or more of these areas in the Epidemiology Branch and leading and working with teams throughout DCVS/NHLBI. Ideal candidates will have an outstanding record of research accomplishments and experience with clinical- and/or population-based observational studies in chronic disease epidemiology with excellent interpersonal and communication skills and the ability to develop and oversee complex research programs.
Qualifications
Required
- U.S. citizen; doctoral degree (PhD or equivalent) with major academic study related to the medical field, health sciences, or allied sciences appropriate to the work of these positions
- Ability to synthesize research findings and develop a broad vision that will advance cardiovascular disease prevention and treatment
- Skill in communicating with scientists and with a sophisticated lay audience
Preferred
- Training and expertise in chronic disease epidemiology and in at least one of the following areas: molecular biology, genetics, multi-omics, and/or bioinformatics; clinical informatics and/or phenomics; health disparities and social determinants of health; and/or women’s health, ideally including maternal health
- Experience with clinical- and/or population-based observational studies in cardiovascular epidemiology
To Apply
Visit https://www.nhlbi.nih.gov/about/working-at-nhlbi/job-opportunities regularly to access the link to the NHLBI Health Scientist Administrator in the Epidemiology Branch job announcement (GS-12/13/14).
For More Information
Contact Yuling Hong, MD, PhD at yuling.hong@nih.gov, Sean Coady, MS, MA at coadys@nhlbi.nih.gov, or Jared Reis, PhD at reisjp@nhlbi.nih.gov.
The U.S. Department of Health and Human Services (HHS), NIH, and NHLBI are equal opportunity employers committed to equity, diversity, and inclusion.
The NHLBI Names Dr. Yuling Hong Chief of the Epidemiology Branch in the Division of Cardiovascular Sciences
The Division of Cardiovascular Sciences (DCVS) of the NHLBI is delighted to welcome Yuling Hong, MD, PhD, FAHA, as the Chief of the Epidemiology Branch effective July 19, 2020.
Dr. Hong comes to the National Heart, lung, and Blood Institute from the Centers for Disease Control and Prevention (CDC), where he served for more than 10 years as Associate Director for Science in the Division for Heart Disease and Stroke Prevention. He also holds an Adjunct Professorship in the Department of Epidemiology, Rollins School of Public Health at Emory University. His vast experience and expertise in leading cardiovascular epidemiology efforts are further reflected by his prior roles: the Director of Epidemiology and Research Services at the American Heart Association (AHA); Associate Professor at the Department of Health Evaluation Sciences at Penn state University College of Medicine; and the Director of Biostatistics and Epidemiology and the Senior Science and Medicine Advisor at the AHA. Dr. Hong has received numerous honors and awards in his career at the CDC and AHA, including the CDC and ATSDR Honor Award for Excellence in Program or Policy Evaluation, CDC’s Center for Global Health Excellence in Program Delivery, and the AHA CEO award for excellent work in the development, implementation and on-going enhancement of the Positioning of Science Information project. Over his distinguished career, Dr. Hong has served as a reviewer for over 30 scientific journals and published over 145 manuscripts.
Dr. Hong received his PhD in Cardiovascular/Genetic Epidemiology from the Karolinska Institute, Stockholm, Sweden; his MS in Epidemiology from the Erasmus University, Rotterdam, the Netherlands; and his Bachelor of Medicine (MD equivalent) from Shanghai Medical University, China.
As previously reported on this Digital Forum, an NHLBI working group comprised of selected members of the NHLBI Advisory Council and Board of External Experts presented a set of seven recommendations for transforming population research to the NHLBI Council in 2014. The recommendations were subsequently published in 2015 (Roger VL et al. Strategic Transformation of Population Studies: Recommendations of the Working Group on Epidemiology and Population Sciences From the National Heart, Lung, and Blood Advisory Council and Board of External Experts. Am J. Epidemiol 2015;181(6):363-367). In its Recommendation 7, the working group advised the NHLBI to “implement a competitive peer review–based model for its portfolio of large epidemiologic and population studies,” in which funding decisions for study infrastructure are separated from peer review for innovative research content.
Consistent with that Recommendation 7, NHLBI recently announced its intent to fund a limited home-based exam in the Women’s Health Initiative (WHI). (See NIH Guide Notice HL-20-750.) The home-based exam, which will take place beginning in April 2022, will serve as a platform for investigator-initiated, peer-reviewed, independently funded exam components that will enrich the exam data collection with additional hypothesis-driven content. The intent of Notice HL-20-750; is to allow time for interested researchers to comply with WHI requirements and develop NIH grant applications to fund exam components addressing innovative research questions in WHI.
This table summarizes timing considerations for submitting grant applications proposing exam components for the WHI limited home exam. (See this webpage for more information about NIH grant application cycles, due dates, etc.)
Potential applicants may wish to consider the following:
- Receipt of new (A0) applications received by the January 2021 Council Cycle (Cycle II) standard receipt dates would allow time for review and potential funding before the exam cycle begins. Receipt of resubmission (A1) applications for the following October 2021 Council (Cycle 1) would allow time for review and potential funding before the exam cycle begins.
Applicants will need to consider timing of their data collection relative to that of the planned exam and any additional time and associated costs that may be required to complete their exam components as proposed.
If you are interested in partnering with WHI in developing and obtaining funding for innovative content for the upcoming exam, please carefully read the NIH Guide Notice (HL-20-750) and visit the WHI website for its ancillary studies policies and other relevant information.
NHLBI Announces Plan to Fund a Limited Framingham Heart Study Exam
As previously reported on this Digital Forum, an NHLBI working group comprised of selected members of the NHLBI Advisory Council and Board of External Experts presented a set of seven recommendations for transforming population research to the NHLBI Council in 2014. The recommendations were subsequently published in 2015 (Roger VL et al. Strategic Transformation of Population Studies: Recommendations of the Working Group on Epidemiology and Population Sciences From the National Heart, Lung, and Blood Advisory Council and Board of External Experts. Am J. Epidemiol 2015;181(6):363-367). In its Recommendation 7, the working group advised the NHLBI to “implement a competitive peer review–based model for its portfolio of large epidemiologic and population studies,” in which funding decisions for study infrastructure are separated from peer review for innovative research content.
Consistent with that Recommendation 7, the NHLBI recently announced its intent to fund a limited clinic exam cycle in the Framingham Heart Study (FHS). The exam, which will take place beginning on or about January 2, 2022, will serve as a platform for investigator-initiated, peer-reviewed, independently funded exam components that will enrich the exam data collection with additional hypothesis-driven content. The intent of Notice NOT-HL-19-732 is to allow time for interested researchers to comply with FHS requirements and develop NIH grant applications to fund exam components addressing innovative research questions in FHS.
Table 1 summarizes timing considerations for submitting grant applications proposing exam components for FHS clinic exam cycle. (Visit this link for more information about NIH grant application cycles, due dates, etc.)
Potential applicants may wish to consider the following:
- Receipt of new (A0) applications received by the January 2021 Council Cycle (Cycle II) standard receipt dates would allow time for review and potential funding before the exam cycle begins. Receipt of resubmission (A1) applications for the following October 2021 Council (Cycle 1) would allow time for review and potential funding before the exam cycle begins.
Applicants will need to consider timing of their data collection relative to that of the planned exam and any additional time and associated costs that may be required to complete their exam components as proposed.
If you are interested in partnering with FHS in developing and obtaining funding for innovative content for the upcoming exam, please carefully read the NIH Guide Notice and visit the FHS website for its ancillary studies policies and other relevant information.
MESA Is Accepting Exam 7 Ancillary Study Proposals
The Multi-Ethnic Study of Atherosclerosis (MESA) is encouraging exam-related ancillary study proposals for a potential Exam 7. The exam is anticipated to begin in October 2021. Please see the December 11, 2018 DIGITAL FORUM for more information. The optimal NIH grant submission date, which allows time for a re-submission is February 5, 2020. If you are interested in partnering with MESA in developing and obtaining funding for innovative content for MESA’s upcoming Exam 7, please visit the MESA website for details regarding MESA ancillary study policies and time-frames for submission and approval. For questions, please contact the MESA Coordinating Center.
NHLBI Announces Plan to Fund a Limited Exam 7 in the Multi-Ethnic Study of Atherosclerosis (MESA)
As previously reported on this Digital Forum, an NHLBI working group comprised of selected members of the NHLBI Advisory Council and Board of External Experts presented a set of seven recommendations for transforming population research to the NHLBI Council in 2014. The recommendations were subsequently published in 2015 (Roger VL et al. Strategic Transformation of Population Studies: Recommendations of the Working Group on Epidemiology and Population Sciences From the National Heart, Lung, and Blood Advisory Council and Board of External Experts. Am J. Epidemiol 2015;181(6):363-367). In its Recommendation 7, the working group advised the NHLBI to “implement a competitive peer review–based model for its portfolio of large epidemiologic and population studies,” in which funding decisions for study infrastructure are separated from peer review for innovative research content.
Consistent with that Recommendation 7, the NHLBI recently announced its intent to fund a limited clinic exam cycle in the Multi-Ethnic Study of Atherosclerosis (MESA). (See NIH Guide Notice NOT-HL-18-668.) The exam, which will take place beginning on or about October 19, 2021, will serve as a platform for investigator-initiated, peer-reviewed, independently funded exam components that will enrich the exam data collection with additional hypothesis-driven content. The intent of NOT-HL-18-668 is to allow time for interested researchers to comply with MESA requirements and develop NIH grant applications to fund exam components addressing innovative research questions in MESA.
The Table summarizes timing considerations for submitting grant applications proposing exam components for MESA’s Exam 7. (See this website for more information about NIH grant application cycles, due dates, etc.)
Potential applicants may wish to consider the following:
- New (A0) grant applications received by the October 2020 Council Cycle (Cycle II) standard due dates and that receive fundable scores may be funded with ample time for planning and preparation of the Exam 7 data collection.
- Resubmitted (A1) applications received by the January 2021 Council Cycle (Cycle II) standard due dates and that receive fundable scores may also be funded with ample time for planning and preparation of the Exam 7 data collection.
- Receipt of resubmitted (A1) applications by the May 2021 Council Cycle (Cycle III) standard due dates and that receive fundable scores would enable awards approximately three months at most before Exam 7 is anticipated to begin. In such cases, it will have to be determined whether this will be enough time for planning and preparation for the exam component(s) before Exam 7 commences. For these and any later due dates, applicants will need to consider timing of their data collection relative to that of the planned exam and any additional time and associated costs they may require to complete their exam components as proposed.
If you are interested in partnering with MESA in developing and obtaining funding for innovative content for MESA’s upcoming Exam 7, carefully read NOT-HL-18-668 and visit the MESA website for its ancillary studies policies and other relevant information.
In recent posts on this Digital Forum, NHLBI announced plans to fund limited examinations in several of its population-based cohort studies. NHLBI would now like to announce its intent to fund a new limited Phase VII clinic examination in the Strong Heart Study (SHS; see NIH Guide Notice NOT-HL-19-687). The exam, which will take place from approximately February 15, 2022 through February 14, 2024, will serve as a platform for investigator-initiated, peer-reviewed, independently funded exam components that will enrich the exam data collection with additional hypothesis-driven content. The intent of Notice HL-19-687 is to allow ample time for interested researchers to comply with SHS requirements and develop NIH grant applications to fund exam components addressing innovative research questions in SHS. It is also to inform interested investigators that the SHS invites investigators to discuss ideas for potential collaborations/ancillary studies with the SHS investigators at the SHS Steering Committee meeting on June 11-12, 2019 in Oklahoma City, Oklahoma.
The Table summarizes timing considerations for submitting grant applications proposing components for the SHS Phase VII exam. (See this website for more information about NIH grant application cycles, due dates, etc.)
Potential applicants may wish to consider the following:
- New (A0) applications and resubmission (A1) applications received by the January 2020 Council Cycle (Cycle II) and that receive fundable scores would enable an award approximately 14 months before the SHS Phase VII begins.
- New (A0) applications and resubmission (A1) applications received by the May 2020 Council Cycle (Cycle III) and that receive fundable scores would enable an award approximately 10 months before the SHS Phase VII begins.
- New (A0) applications and resubmission (A1) applications received by the October 2020 Council Cycle (Cycle I) and that receive fundable scores would enable an award approximately 7 months before the SHS Phase VII begins.
- For new (A0) applications received by the January 2021 Council Cycle (Cycle II) standard due dates that do not receive fundable scores, resubmission (A1) applications will be funded approximately 3 months before the SHS Phase VII begins. It will have to be determined whether this will be enough time to begin data collection prior to the start of the SHS Phase VII exam. If not, a start date during the first year of the Phase VII exam may be possible.
Therefore, for grant applications received after the October 2020 Council Cycle (Cycle I), applicants will need to consider timing of their data collection relative to that of the planned exam and any additional time and associated costs that may be required to complete their exam components as proposed.
If you are interested in partnering with the SHS in developing and obtaining funding for innovative content for the upcoming limited Phase VII exam, please carefully read the NIH Guide Notice HL-19-687 and visit the SHS website for its ancillary studies policies and other relevant information.
NHLBI Announces Plan to Fund a Limited Framingham Heart Study Exam
As previously reported on this Digital Forum, an NHLBI working group comprised of selected members of the NHLBI Advisory Council and Board of External Experts presented a set of seven recommendations for transforming population research to the NHLBI Council in 2014. The recommendations were subsequently published in 2015 (Roger VL et al. Strategic Transformation of Population Studies: Recommendations of the Working Group on Epidemiology and Population Sciences From the National Heart, Lung, and Blood Advisory Council and Board of External Experts. Am J. Epidemiol 2015;181(6):363-367). In its Recommendation 7, the working group advised the NHLBI to “implement a competitive peer review–based model for its portfolio of large epidemiologic and population studies,” in which funding decisions for study infrastructure are separated from peer review for innovative research content.
Consistent with that Recommendation 7, the NHLBI recently announced its intent to fund a limited clinic exam cycle in the Framingham Heart Study (FHS). (See NIH Guide Notice NOT-HL-17-572.) The exam, which will take place beginning on or about August 1, 2019, will serve as a platform for investigator-initiated, peer-reviewed, independently funded exam components that will enrich the exam data collection with additional hypothesis-driven content. The intent of NOT-HL-17-572 is to allow time for interested researchers to comply with FHS requirements and develop NIH grant applications to fund exam components addressing innovative research questions in FHS.
The Table summarizes timing considerations for submitting grant applications proposing exam components for the FHS clinic exam cycle. (See this website for more information about NIH grant application cycles, due dates, etc.)
Potential applicants may wish to consider the following:
- Receipt of new (A0) applications by the October 2018 Council Cycle (Cycle I) standard receipt dates would allow time for review and potential funding before the exam cycle begins. Receipt of resubmission (A1) applications for the following May 2019 Council Cycle (Cycle III) would allow time for review before the exam cycle begins; funding would occur approximately one month prior to the anticipated exam start date.
- Receipt of new (A0) applications received by the January 2019 Council Cycle (Cycle II) standard receipt dates would allow time for review and potential funding before the exam cycle begins. Receipt of resubmission (A1) applications for the following October 2019 Council (Cycle 1) would occur after the proposed exam start date.
Applicants will need to consider timing of their data collection relative to that of the planned exam and any additional time and associated costs that may be required to complete their exam components as proposed.
If you are interested in partnering with FHS in developing and obtaining funding for innovative content for the upcoming exam, please carefully read NOT-HL-17-572 and visit the FHS website for its ancillary studies policies and other relevant information.
nhlbiepi.wordpress.com 